Dr. Karim Chamie, MD
Claim this profileUCLA - University of California
Affiliated Hospitals
UCLA - University Of California
UCLA / Jonsson Comprehensive Cancer Center
Clinical Trials Karim Chamie, MD is currently running
Pembrolizumab + Enfortumab Vedotin
for Urothelial Carcinoma
This phase II clinical trial tests how well pembrolizumab plus enfortumab vedotin prior to and after radical nephroureterectomy works in treating patients with high-risk upper tract urothelial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Enfortumab vedotin (EV) is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Radical nephroureterectomy (RNU) is the surgical removal of a kidney and its ureter. Giving pembrolizumab plus enfortumab vedotin before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed and giving pembrolizumab after surgery may kill any remaining cancer cells.
Recruiting
1 award
Phase 2
BCG + N-803
for Bladder Cancer
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
Recruiting
1 award
Phase 1 & 2
8 criteria
More about Karim Chamie, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Karim Chamie, MD has experience with
- BCG
- N-803
- Enfortumab Vedotin
- Nephroureterectomy
- Pembrolizumab
- Zalifrelimab (UGN-301)
Breakdown of trials Karim Chamie, MD has run
Bladder Cancer
Transitional Cell Carcinoma
Urothelial Carcinoma
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karim Chamie, MD specialize in?
Karim Chamie, MD focuses on Bladder Cancer and Transitional Cell Carcinoma. In particular, much of their work with Bladder Cancer has involved treating patients, or patients who are undergoing treatment.
Is Karim Chamie, MD currently recruiting for clinical trials?
Yes, Karim Chamie, MD is currently recruiting for 3 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Karim Chamie, MD has studied deeply?
Yes, Karim Chamie, MD has studied treatments such as BCG, N-803, Enfortumab Vedotin.
What is the best way to schedule an appointment with Karim Chamie, MD?
Apply for one of the trials that Karim Chamie, MD is conducting.
What is the office address of Karim Chamie, MD?
The office of Karim Chamie, MD is located at: UCLA - University of California, Los Angeles, California 90095 United States. This is the address for their practice at the UCLA - University of California.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.